Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South

Pharmacogenetics and Genomics

Volumn 21, Issue 12, 2011, Pages 867-875

  Coombes, R Hunter ^a   Crow, J Allen ^a   Dail, Mary Beth ^a   Chambers, Howard W ^b   Wills, Robert W ^a   Bertolet, Barry D ^c   Chambers, Janice E ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b MISSISSIPPI STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

atherosclerosis; cardiovascular disease; coronary artery disease; health disparities; paraoxonase

Indexed keywords

ADIPHENINE; ARYLDIALKYLPHOSPHATASE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SMOKING; UNITED STATES;

EID: 81055156099     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834cebc6     Document Type: Article

References (36)

1. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15:1812-1818.
2. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005; 90:1728-1733. (Pubitemid 40464045)
3. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-287. (Pubitemid 28335041)
4. Gaidukov L, Tawfik DS. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005; 44:11843-11854. (Pubitemid 41262719)
5. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-154.
6. Aldridge WN, Davison AN. The mechanism of inhibition of cholinesterases by organophosphorus compounds. Biochem J 1953; 55:763-766.
7. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004; 37:1304-1316. (Pubitemid 39349234)
8. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005; 181:9-18. (Pubitemid 40804688)
9. Tward A, Xia YR,Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 2002; 106:484-490. (Pubitemid 34803695)
10. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34:774-784. (Pubitemid 36288542)
11. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 2000; 275:17527-17535. (Pubitemid 30430794)
12. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996; 14:334-336.
13. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000; 20:516-521. (Pubitemid 30086111)
14. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608. (Pubitemid 23311330)
15. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3:73-76. (Pubitemid 23063292)
16. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101: 2510-2517. (Pubitemid 30366256)
17. Costa LG, Cole TB, Jarvik GP, Furlong CE. Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54:371-392. (Pubitemid 37386402)
18. Gupta N, Singh S, Maturu VN, Sharma YP, Gill KD. Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One 2011; 6:e17805.
19. Mohamed RH, Mohamed RH, Karam RA, Abd El-Aziz TA. The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clinical Biochemistry 2010; 43:553-558.
20. Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res 2006; 47:2492-2502. (Pubitemid 44936111)
21. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299:1265-1276. (Pubitemid 351439073)
22. Wang M, Lang X, Zou L, Huang S, Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: a meta-analysis based on 88 case-control studies. Atherosclerosis 2011; 214:377-385.
23. Richter RJ, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-753. (Pubitemid 30011938)
24. Richter RJ, Jarvik GP, Furlong CE. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet 2008; 1:147-152.
25. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart Disease and Stroke Statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123:e18-e209.
26. Perry HM, Roccella EJ. Conference report on stroke mortality in the Southeastern United States. Hypertension 1998; 31:1206-1215. (Pubitemid 28248817)
27. Chen J, Kumar M, Chan W, Berkowitz G,Wetmur JG. Increased influence of genetic variation on PON1 activity in neonates. Environ Health Perspect 2003; 111:1403-1409. (Pubitemid 37063172)
28. Davis KA, Crow JA, Chambers HW, Meek EC, Chambers JE. Racial differences in paraoxonase-1 (PON1): a factor in the health of southerners? Environ Health Perspect 2009; 117:1226-1231.
29. McKenney JM. Update on the National Cholesterol Education Program adult treatment panel III guidelines: getting to goal. Pharmacotherapy 2003; 23:26S-33S. (Pubitemid 37158771)
30. Chambers JE, Chambers HW. Time course of inhibition of acetylcholinesterase and aliesterases following parathion and paraoxon exposures in rats. Toxicol Appl Pharmacol 1990; 103:420-429. (Pubitemid 20154721)
31. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989.
32. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005; 46: 1239-1247. (Pubitemid 43109838)
33. Yusuf PS, Hawken S, O ̂ unpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952. (Pubitemid 39208455)
34. Paragh G, Harangi M, Seres I. Effect of lipid lowering medications on PON1. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in diease development and xenobiotic metabolism. Dordrecht, The Netherlands: Springer; 2008. pp. 251-266.
35. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol 2003; 23:1465-1471. (Pubitemid 36994538)
36. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-2447.